Scholarlink

<p>The increasing prevalence of non-tuberculous mycobacterial lung infection represents a global challenge. Infections caused by <i>Mycobacteroides abscessus</i> commonly occur in individuals with underlying predisposing lung diseases such as cystic fibrosis (CF), non-CF-bronchiectasis, chronic obstructive pulmonary disease (COPD), and tuberculosis (TB). The unmet need in the treatment of <i>M. abscessus</i> pulmonary infection is driven by multidrug-resistance, ability to form biofilms, lengthy treatment, and drug-related side effects. Pravibismane was evaluated for its potential to reduce <i>M. abscessus</i> burden in vitro and in vivo. Pravibismane exhibited significantly lower (16- to 32-fold) minimum inhibitory concentrations (MICs) compared to amikacin. Treatment of THP-1 <i>M. abscessus</i>-infected macrophages with pravibismane led to a rapid reduction in intracellular <i>M. abscessus</i> while maintaining the viability of the THP-1 macrophages. Pravibismane demonstrated to be well-tolerated and efficacious in a chronic mouse <i>M. abscessus</i> lung infection model in which 28-day treatment with inhaled pravibismane substantially reduced the burden of <i>M. abscessus</i> in murine lung tissues. Overall, pravibismane exhibited promising efficacy by reducing intracellular <i>M. abscessus</i> levels in vitro and in a chronic mouse infection model. These preclinical results warrant investigation of pravibismane’s ability to treat <i>M. abscessus</i> lung infection in relevant patient populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vitro and in vivo antibacterial activity of pravibismane against Mycobacteroides abscessus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月25日

查看全文
  • Amy Leestemaker-Palmer,
  • Bailey Keefe,
  • Luiz E. Bermudez,
  • Brett H. J. Baker

摘要

The increasing prevalence of non-tuberculous mycobacterial lung infection represents a global challenge. Infections caused by Mycobacteroides abscessus commonly occur in individuals with underlying predisposing lung diseases such as cystic fibrosis (CF), non-CF-bronchiectasis, chronic obstructive pulmonary disease (COPD), and tuberculosis (TB). The unmet need in the treatment of M. abscessus pulmonary infection is driven by multidrug-resistance, ability to form biofilms, lengthy treatment, and drug-related side effects. Pravibismane was evaluated for its potential to reduce M. abscessus burden in vitro and in vivo. Pravibismane exhibited significantly lower (16- to 32-fold) minimum inhibitory concentrations (MICs) compared to amikacin. Treatment of THP-1 M. abscessus-infected macrophages with pravibismane led to a rapid reduction in intracellular M. abscessus while maintaining the viability of the THP-1 macrophages. Pravibismane demonstrated to be well-tolerated and efficacious in a chronic mouse M. abscessus lung infection model in which 28-day treatment with inhaled pravibismane substantially reduced the burden of M. abscessus in murine lung tissues. Overall, pravibismane exhibited promising efficacy by reducing intracellular M. abscessus levels in vitro and in a chronic mouse infection model. These preclinical results warrant investigation of pravibismane’s ability to treat M. abscessus lung infection in relevant patient populations.